CLCN1 and myasthenia gravis: Recently, partial inhibition of the skeletal muscle ClC‐1 chloride channel with a novel small molecule ClC‐1 inhibitor (NMD670) has been shown to enhance NMJ transmission and improve symptoms in animal models and patients with myasthenia gravis (MG).14